Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Moringa Sponsor, LP and related parties filed Amendment No. 2 to their Schedule 13D on Silexion Therapeutics Corp. They report beneficial ownership of 1,382,346 ordinary shares, representing 32.99% of Silexion’s ordinary shares outstanding, calculated using 4,189,954 shares reported in Silexion’s Form 10-Q as of March 31, 2026.
The reported holdings include 6,970 ordinary shares, 372 ordinary shares underlying warrants, 450,000 ordinary shares issued on September 15, 2025 upon conversion of $1.8 million under an Amended and Restated Promissory Note, and 925,004 ordinary shares issued on May 14, 2026 upon conversion of $0.4 million under the same note. The reporting persons state they are filing out of an abundance of caution and expressly dispute the validity of the 450,000 and 925,004 shares and do not concede beneficial ownership of them.
Silexion Therapeutics Corp has implemented a 1-for-10 reverse share split of its ordinary shares to help maintain compliance with Nasdaq’s minimum bid price requirements. The split became effective after the close of business on May 28, 2026, with trading on a split-adjusted basis beginning May 29, 2026 under the existing symbol SLXN.
Following the reverse split, authorized share capital remains at $796,500, now divided into 5,900,000 ordinary shares with par value increasing from $0.0135 to $0.135 per share. As of April 7, 2026, issued shares were consolidated from 4,074,710 to 407,471. The company also adjusted its public and private warrants so each whole warrant now reflects the 1-for-10 ratio and carries an exercise price of $15,525.00 per ordinary share, with no fractional shares issued on exercise.
Silexion Therapeutics Corp is implementing a 1-for-10 reverse share split of its ordinary shares. The split becomes effective after market close on May 28, 2026, with shares trading on a reverse split-adjusted basis on the Nasdaq Capital Market from May 29, 2026 under the symbol SLXN.
Every ten ordinary shares will be automatically combined into one share, and the par value will increase from $0.0135 to $0.135 per share. No fractional shares will be issued; eligible DTC participants will have any fractional entitlements rounded up to the nearest whole share. The company states that the reverse split is intended, among other things, to help maintain compliance with Nasdaq’s minimum bid price requirement and support its strategic plans as it advances its RNAi candidate SIL204 toward a Phase 2/3 trial in locally advanced pancreatic cancer.
Silexion Therapeutics Corp filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment is narrowly focused on correcting typographical errors in Item 9A so that the date of management’s evaluation of internal control over financial reporting is properly stated as December 31, 2025 rather than December 31, 2024.
Management, including the Chief Executive Officer and Chief Financial Officer, evaluated disclosure controls and procedures and internal control over financial reporting as of December 31, 2025 using the COSO 2013 framework and concluded both were effective. As a non-accelerated, emerging growth company, Silexion is not required to obtain an auditor attestation on internal control.
The company states there were no changes in internal control over financial reporting during the three-month period ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, these controls. Other disclosures from the original Form 10-K remain unchanged, aside from updated exhibits and certifications. As of June 30, 2025, non-affiliate ordinary shares had an aggregate market value of $6,619,600, and 3,330,785 ordinary shares were outstanding as of March 10, 2026.
Silexion Therapeutics reported first quarter 2026 results and highlighted progress for its lead RNAi candidate SIL204 in locally advanced pancreatic cancer. The Israeli Ministry of Health approved initiation of a Phase 2/3 clinical trial, and a Clinical Trial Application was submitted in Germany under the EU Clinical Trials Regulation, keeping trial initiation on track for the second quarter of 2026.
For the three months ended March 31, 2026, Silexion recorded a net loss of $2.7 million compared with $1.7 million a year earlier, driven by higher research and development expense of $1.4 million and general and administrative expense of $1.4 million. Cash and cash equivalents declined to $2.4 million from $6.0 million as of December 31, 2025, while shareholders’ equity fell to $0.3 million from $2.6 million, and a related party promissory note of $1.6 million was reclassified into current liabilities. Management noted warrant exercise inducements, at-the-market usage and shareholder approval for a prospective reverse share split as steps to support both clinical development and continued Nasdaq listing.
Silexion Therapeutics Corp reports a wider net loss as it funds its KRAS-targeted RNAi cancer pipeline. For the three months ended March 31, 2026, net loss rose to $2.7M from $1.7M a year earlier, driven by higher research and development spending of $1.4M versus $0.6M, mainly for toxicology work, product development and trial preparation. General and administrative expenses increased to $1.4M from $1.1M, reflecting professional services and share-based compensation for directors and executives.
Cash and cash equivalents fell to $2.4M at March 31, 2026 from $6.0M at December 31, 2025, with operating activities using $3.6M of cash in the quarter. Shareholders’ equity declined sharply to $0.3M from $2.6M, prompting management to conclude there is substantial doubt about the company’s ability to continue as a going concern.
To bolster liquidity, Silexion raised modest funds under an at-the-market facility in the quarter and, after quarter-end, completed a large warrant exercise inducement and additional ATM sales, and increased its authorized share capital. Shareholders also approved a 1-for-10 reverse share split intended to support continued Nasdaq listing and future capital-raising.
Silexion Therapeutics Corp entered into an inducement agreement with holders of 1,995,092 existing warrants to exercise them for cash at a reduced price of $0.50 per share, in exchange for 3,990,184 new warrants at the same exercise price. The company expects about $1.0 million in gross proceeds before fees, which it plans to use for general corporate purposes. New Series C and Series D warrants become exercisable only after shareholder approval and effectiveness of a resale registration statement and include 4.99% or 9.99% ownership limits, cashless exercise mechanics and five-year or 24‑month terms.
Silexion Therapeutics Corp Schedule 13G/A amendment: Lind Global-related entities report beneficial ownership of 212,500 securities, representing 4.96% of the class. The holdings consist of 106,250 Series A-1 Warrants and 106,250 Series A-2 Warrants, each subject to an exercise limitation that prevents exercise if such exercise would raise beneficial ownership above 9.9%. The filing lists Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton as reporting persons and shows sole voting and dispositive power for 212,500 instruments.
Silexion Therapeutics reported early laboratory findings suggesting its lead RNAi candidate SIL204 may have an immune-modulating effect in KRAS-driven cancers. In a preclinical study using human pancreatic cancer cells with a KRAS G12R mutation, SIL204 treatment led to a statistically significant increase in MHC-I (HLA-ABC) expression, a key signal that helps cytotoxic T cells recognize tumor cells. The company notes this could support future evaluation of SIL204 in combination with anti-PD-1 immunotherapies such as pembrolizumab, although these results remain preliminary and preclinical. Silexion is advancing SIL204 towards clinical trials in Israel and the European Union for locally advanced pancreatic cancer.
Silexion Therapeutics Corp is advancing its lead RNAi cancer drug SIL204 by starting Good Manufacturing Practice (GMP) clinical batch manufacturing with Catalent at its Limoges, France facility. These clinical batches will be used as investigational medicinal product for the safety run-in segment of a planned Phase 2/3 trial in locally advanced pancreatic cancer.
The company also received approval from the Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center for the planned Phase 2/3 study at this leading Israeli oncology site, following prior authorization from the Israeli Ministry of Health and a Clinical Trial Application submission in Germany. Together, the manufacturing progress and multi-country regulatory steps move SIL204 closer to first patient dosing in a Phase 2/3 trial combining SIL204 with standard chemotherapy and using a dual-route (intratumoral and systemic) administration strategy.